À̹ÌÁö È®´ë Celltrion Pharm on Monday announced its first commercial rollout in human immunodeficiency virus (HIV) drug CT-G7 for the global market.
CT-G7 developed by Celltrion is a three-in-one-tablet for HIV treatment. The modified regimen received tentative approval from the U.S. Food and Drug Administration (FDA) in April. Celltrion recently signed $16 million supply deals with international procurement organizations. Additional contracts worth $20 million in total are due in the second half of this year, according to the company.
The shipment of CT-G7 means another promising chemical compound to Celltrion Pharm¡¯s pipeline for global marketing following antibiotic drug CT-G1 (Linezolid) and HIV treatment CT-G2 (Temixys). Celltrion is also at a final stage of commercial production for diabetic neuropathy drug CT-G4, which will be added to Celltrion Pharma¡¯s global chemical pipeline this year.
According to the Clinton Health Access Initiative (CHAI), the global HIV treatment market, including CT-G7, generated around 1.2 trillion won ($1 billion) in sales last year. Celltrion Group aims to represent about 10 percent of this market during its initial business stage.
By Pulse
[¨Ï Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]